4548
SEIKAGAKU CORPORATION
生化学工業
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2022
34,851
Mar 2023
33,456
Mar 2024
36,213
Mar 2025
39,374
Mar 2026
36,645
Operating profit(million JPY)
Mar 2022
4,495
Mar 2023
2,114
Mar 2024
433
Mar 2025
1,333
Mar 2026
-660
Operating profit margin(%)
Mar 2022
12.9
Mar 2023
6.32
Mar 2024
1.2
Mar 2025
3.39
Mar 2026
-1.8
Profit before tax(million JPY)
Mar 2022
5,395
Mar 2023
3,069
Mar 2024
1,691
Mar 2025
1,933
Mar 2026
1,510
Profit(million JPY)
Mar 2022
3,733
Mar 2023
2,236
Mar 2024
2,186
Mar 2025
1,214
Mar 2026
1,473
Total assets(million JPY)
Mar 2022
75,244
Mar 2023
75,625
Mar 2024
81,795
Mar 2025
83,872
Mar 2026
86,344
Cash and cash equivalents(million JPY)
Mar 2022
23,367
Mar 2023
25,798
Mar 2024
18,701
Mar 2025
18,322
Mar 2026
12,059
Cash flows from operating activities(million JPY)
Mar 2022
8,192
Mar 2023
1,574
Mar 2024
513
Mar 2025
4,429
Mar 2026
-1,347
Cash flows from investing activities(million JPY)
Mar 2022
870
Mar 2023
3,365
Mar 2024
-7,209
Mar 2025
-3,540
Mar 2026
-3,508
Cash flows from financing activities(million JPY)
Mar 2022
-2,151
Mar 2023
-3,244
Mar 2024
-1,461
Mar 2025
-1,571
Mar 2026
-1,677
Return on equity(%)
Mar 2022
5.7
Mar 2023
3.3
Mar 2024
3.1
Mar 2025
1.7
Mar 2026
2
Equity ratio(%)
Mar 2022
88.2
Mar 2023
88.9
Mar 2024
88.4
Mar 2025
87.3
Mar 2026
87.2
Earnings per share(JPY per share)
Mar 2022
66.32
Mar 2023
40.49
Mar 2024
40.08
Mar 2025
22.25
Mar 2026
26.99
Net assets per share(JPY per share)
Mar 2022
1,179.46
Mar 2023
1,232.41
Mar 2024
1,324.82
Mar 2025
1,340.98
Mar 2026
1,379.03
Dividend per share(JPY per share)
Mar 2022
30
Mar 2023
26
Mar 2024
26
Mar 2025
30
Mar 2026
30
Payout ratio(%)
Mar 2022
45.24
Mar 2023
64.21
Mar 2024
64.87
Mar 2025
134.83
Mar 2026
111.15
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.